We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Resverlogix Commences Phase 3 Clinical Trial BETonMACE with Apabetalone

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Resverlogix Commences Phase 3 Clinical Trial BETonMACE with Apabetalone"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Resverlogix Corp. has announced the commencement of a Phase 3 clinical trial called 'BETonMACE' with lead drug apabetalone (RVX-208) in high-risk patients with coronary artery disease (CAD) and type 2 diabetes mellitus (DM).

Resverlogix has received initial approval from the regulatory authority and ethics committee in the first three countries: Belgium, Hungary and Israel, which will represent approximately 15 investigative sites of an expected 175 site trial.

The first site initiation visit was held and with drug now available to the centers, enrollment of patients will commence. Over the course of the coming months, additional investigative sites will be activated.